| Title |
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
|
|---|---|
| Published in |
CNS Drugs, October 2018
|
| DOI | 10.1007/s40263-018-0578-5 |
| Pubmed ID | |
| Authors |
Lesley Taylor, Barry Gidal, Graham Blakey, Bola Tayo, Gilmour Morrison |
X Demographics
The data shown below were collected from the profiles of 46 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 20% |
| Canada | 7 | 15% |
| Japan | 3 | 7% |
| Ireland | 2 | 4% |
| Netherlands | 2 | 4% |
| Guyana | 1 | 2% |
| India | 1 | 2% |
| Spain | 1 | 2% |
| Switzerland | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 16 | 35% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 37 | 80% |
| Practitioners (doctors, other healthcare professionals) | 8 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 446 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 446 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 65 | 15% |
| Student > Master | 51 | 11% |
| Student > Bachelor | 45 | 10% |
| Student > Ph. D. Student | 43 | 10% |
| Other | 41 | 9% |
| Other | 52 | 12% |
| Unknown | 149 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 71 | 16% |
| Medicine and Dentistry | 60 | 13% |
| Biochemistry, Genetics and Molecular Biology | 33 | 7% |
| Neuroscience | 26 | 6% |
| Agricultural and Biological Sciences | 17 | 4% |
| Other | 72 | 16% |
| Unknown | 167 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 165. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2024.
All research outputs
#253,051
of 25,843,331 outputs
Outputs from CNS Drugs
#15
of 1,404 outputs
Outputs of similar age
#5,142
of 364,954 outputs
Outputs of similar age from CNS Drugs
#1
of 21 outputs
Altmetric has tracked 25,843,331 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,404 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,954 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.